FDA recall record

Milrinone Lactate Injection, USP 20mg/20 mL (1mg/mL) recall — FDA D-1144-2023

Failed Impurities/Degradation Specifications

Class IIIclassification
D-1144-2023official record ID
Sep 13, 2023report date

Recall record at a glance

Official recordD-1144-2023
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmCaplin Steriles Limited
Report dateSep 13, 2023
Recall initiation dateAug 14, 2023
Quantity19, 820 vials
LocationGummidipoondi, N/A, India

Official product description

Milrinone Lactate Injection, USP 20mg/20 mL (1mg/mL), packaged in 10 x 20 mL vials per carton, NDC 72485-502-01 (single vial), Rx only, Distributed by: Armas Pharmaceuticals, Inc. Freehold, NJ 07728(USA) Manufactured by: Caplin Steriles Limited, India, NDC 72485-502-10

Why the product was recalled

Failed Impurities/Degradation Specifications

Distribution information

Nationwide in Tennessee

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: E-Mail.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.